ArticleMedical sciences (Basel, Switzerland)2026
Audiometric Monitoring and Its Determinants in Patients Undergoing Chemoradiotherapy for Head and Neck Cancer.
Article in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAudiometric monitoring is recommended for patients receiving ototoxic (chemo)radiotherapy for head and neck cancer (HNC), yet real-world uptake is poorly characterized and potentially inequitable. We quantified the uptake and timing of audiometric testing and examined rural-urban residence and age as candidate determinants. MATERIALS AND
methodsWe conducted a single-center retrospective cohort study of 70 consecutive patients with HNC treated with radiotherapy between November 2024 and September 2025, comparing rural (
resultsAudiometry at treatment initiation was performed in 31/70 patients (44.3%) and repeat audiometry in only 10/70 (14.3%); among tested patients with documented dates, just 19.4% underwent audiometry before the first radiotherapy fraction, so that a true pre-exposure baseline existed for only 6/70 patients (8.6%). Uptake at initiation was 53.7% with concurrent cisplatin, 14.3% with carboplatin, and 36.4% with radiotherapy alone (
conclusionsAudiometric monitoring was incomplete, rarely obtained before irradiation, and steeply age-patterned, whereas rural residence was not associated with lower uptake; structured, exposure-based referral pathways, triggered by planned cisplatin and clinically relevant cochlear dose and applied irrespective of age, are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.